Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BLCM

Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis

Bellicum Pharmaceuticals logo

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Advanced Chart

Key Stats

Today's Range
$0.07
$0.09
50-Day Range
$0.07
$0.10
52-Week Range
$0.06
$1.31
Volume
6,059 shs
Average Volume
22,874 shs
Market Capitalization
$726.57 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Stock News Headlines

Bellicum Pharmaceuticals Inc (BLCM)
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
Bellicum Pharmaceuticals Inc BLCM
Futura Medical plc (FAMDF)
See More Headlines

BLCM Stock Analysis - Frequently Asked Questions

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its quarterly earnings data on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($1.37) by $1.15. The biopharmaceutical company earned $0.70 million during the quarter.

Shares of Bellicum Pharmaceuticals reverse split on the morning of Thursday, February 6th 2020.The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Bellicum Pharmaceuticals (BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), NVIDIA (NVDA), CyberArk Software (CYBR), Gilead Sciences (GILD) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
8/11/2021
Today
7/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLCM
CIK
1358403
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.97 million
Net Margins
N/A
Pretax Margin
-1,492.40%
Return on Equity
N/A
Return on Assets
-157.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.04
Quick Ratio
3.04

Sales & Book Value

Annual Sales
$1.50 million
Price / Sales
0.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
0.33

Miscellaneous

Outstanding Shares
9,720,000
Free Float
8,716,000
Market Cap
$726.57 thousand
Optionable
Not Optionable
Beta
1.39

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:BLCM) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners